Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07528352 · ClinicalTrials.gov registry record · Phase 1
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
A Phase 1 study, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07528352 is a Phase 1 study that is actively recruiting participants, run by University of Utah. The registered enrollment target is 12 participants.
The verdict
NCT07528352, a Phase 1 study, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Interventions
- DRUG Glofitamab
- DRUG Epcoritamab
- RADIATION External Beam Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2031-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07528352
The ClinicalTrials.gov registry entry for NCT07528352 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Glofitamab is the first listed.
NCT07528352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07528352 about?
NCT07528352 is a clinical study titled "External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL". The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
What is the current status of trial NCT07528352?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-06-01. Estimated completion is 2031-06.
What interventions are being tested in trial NCT07528352?
The interventions under investigation include: Glofitamab (DRUG), Epcoritamab (DRUG), External Beam Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT07528352?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.